1. Home
  2. MC vs GH Comparison

MC vs GH Comparison

Compare MC & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Moelis & Company

MC

Moelis & Company

HOLD

Current Price

$71.44

Market Cap

5.3B

Sector

Finance

ML Signal

HOLD

Logo Guardant Health Inc.

GH

Guardant Health Inc.

HOLD

Current Price

$103.37

Market Cap

14.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MC
GH
Founded
2007
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.3B
14.1B
IPO Year
2014
2018

Fundamental Metrics

Financial Performance
Metric
MC
GH
Price
$71.44
$103.37
Analyst Decision
Buy
Strong Buy
Analyst Count
9
21
Target Price
$73.75
$96.48
AVG Volume (30 Days)
822.4K
1.8M
Earning Date
02-04-2026
10-29-2025
Dividend Yield
3.63%
N/A
EPS Growth
446.16
N/A
EPS
3.17
N/A
Revenue
$1,467,580,000.00
$902,569,000.00
Revenue This Year
$27.08
$35.00
Revenue Next Year
$17.26
$26.80
P/E Ratio
$22.58
N/A
Revenue Growth
51.19
30.38
52 Week Low
$47.00
$29.91
52 Week High
$82.89
$112.43

Technical Indicators

Market Signals
Indicator
MC
GH
Relative Strength Index (RSI) 65.76 57.55
Support Level $69.51 $96.28
Resistance Level $71.58 $103.17
Average True Range (ATR) 1.91 3.53
MACD 0.22 -0.70
Stochastic Oscillator 85.55 71.98

Price Performance

Historical Comparison
MC
GH

About MC Moelis & Company

Moelis & Co is an independent investment bank that provides strategic and financial advice to a diverse client base, including corporations, financial sponsors, governments, and sovereign wealth funds. The company assists its clients in achieving their strategic goals by offering comprehensive, globally integrated financial advisory services across all industry sectors. It also advises clients on their critical decisions, including mergers and acquisitions, recapitalizations and restructurings, capital markets transactions, and other corporate finance matters. it generates revenue from advisory transactions. The firm derives a majority of its revenue from the United States followed by Europe and the rest of the World.

About GH Guardant Health Inc.

Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Share on Social Networks: